Towa Pharmaceutical Co. Ltd’s. purchase of the Pensa Investments generics business from Spain’s Esteve exceeded expectations in the Japanese firm’s financial first quarter ended 30 June, overachieving for both net sales and operating profit in the wake of the COVID-19 pandemic.
Net sales of ¥9.96bn ($93
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?